KENNETH MEIER: Open Payments
NPI 1770049264 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$558 in 18 payments from 9 companies in 2025. Trend: 2023 $704 · 2024 $791 · 2025 $558
Food & beverage: $558
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 3 | $257 |
| PFIZER INC. | 4 | $85 |
| Lilly USA, LLC | 4 | $82 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $37 |
| Novo Nordisk Inc | 1 | $27 |
| Esperion Therapeutics, Inc. | 1 | $21 |
| Exact Sciences Corporation | 1 | $17 |
| Acella Pharmaceuticals, LLC | 1 | $16 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $15 |
Products named: AIRSUPRA, FARXIGA, NURTEC ODT, MOUNJARO, XIFAXAN, Rybelsus, NEXLETOL, ELIQUIS.
Industry payments across NV — which companies pay providers there.
